StimLabs Partners with Geistlich to Transform Wound Care Advances

In an exciting development for regenerative medicine, StimLabs has announced an exclusive national distribution agreement with Geistlich, a renowned leader in regenerative technologies. This partnership aims to broaden the spectrum of innovative wound care solutions available within the U.S. market, marking a significant progression for both companies.

The focus of this collaboration is Derma-Gide®, a state-of-the-art advanced wound matrix designed for effective management of wounds. By utilizing Derma-Gide, healthcare providers can leverage a clinically proven solution that enhances the body's natural healing capabilities. Incorporating a highly refined, dual-sourced porcine-derived advanced wound matrix, Derma-Gide is expected to revolutionize wound care by significantly reducing closure costs, allowing healthcare facilities to maintain patient care without sacrificing budgetary concerns.

Expanding Accessible Care

John Daniel, the CEO and Founder of StimLabs, emphasized the core philosophy of their mission: "Our objective has been to foster advancements in regenerative medicine while ensuring that patients receive the most effective treatment options available. By collaborating with Geistlich, we are expanding our capacity to meet diverse healthcare needs efficiently."

This agreement is also particularly notable as it positions Derma-Gide among the few products eligible for reimbursement under the most recent Medicare policy regarding diabetic foot ulcers (DFUs). With expanded commercial coverage based on credible clinical data, healthcare providers across the nation can now offer Derma-Gide as a treatment option for a variety of acute and chronic wounds.

Tom Dion, executive vice president and chief commercial officer of StimLabs, added, "The significance of Derma-Gide extends beyond innovation; it aligns with our commitment to providing differentiated solutions for clinicians, improving patient outcomes in a more effective manner."

The Legacy of Geistlich

Geistlich, with a legacy spanning over 170 years in regenerative medicine, is globally recognized for its commitment to quality. The company operates with a focus on exceptional Swiss manufacturing standards, ensuring comprehensive support to clinicians in regenerative medicine through continual scientific research and innovative education programs. Established in 1851, Geistlich is well-equipped with 15 international affiliates and over 800 employees, successfully reaching approximately 90 markets worldwide.

Commenting on this strategic alliance, Geistlich CEO Diego Gabathuler said, "StimLabs embodies the spirit of innovation and is strongly aligned with our endeavor to improve patient lives. Their proven commercial execution makes them an ideal partner to pave the way for our leading wound care products to reach those who need them most across the U.S."

Both companies are devoted to providing superior products and improving the healthcare experience for both patients and professionals alike. As they move forward, the implementation of Derma-Gide is anticipated to mark a transformative phase in how wounds are managed and treated, pushing the boundaries of traditional healing methodologies.

In conclusion, this partnership not only signifies growth for StimLabs’ product portfolio but also represents a step toward redefining wound care strategy in alignment with modern healthcare demands. The implications of this collaboration could lead to a paradigm shift in treatment approaches for a range of complications, affirming both firms' commitment to better health outcomes. For further details, visit StimLabs and Geistlich.